drugset / Trial / NCT06686108
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Phase 2
Recruiting
59 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelPrevention
Summary
This study is a prospective, phase II clinical trial with the primary objective of assessing the effectiveness of demethylating agents combined with venetoclax in the prevention of recurrence after allogeneic hematopoietic stem cell transplantation (allo-HSCT) of high risk T-lymphoblastic lymphoma/leukemia (T-LBL/ALL) patients.
Timeline
- Start
- 2024-10-30
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 32 mg/m2 | Other |
| Subject | Decitabine | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |